MetaCap

CVRx Inc. (CVRX)

NASDAQ: CVRXHealth CareMedical/Dental InstrumentsUSD

0.501-0.0319 (-5.99%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CVRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$14.27M
EPS (TTM)
-$2.00
52-week range
0.497 – 10.28
Day range
0.4972 – 0.569
Volume / Avg
519.86K / 744.45K
Beta
—

52-week range

$0.497$10.28

CVRX stock today

CVRx (CVRX) closed at $0.501 on Nov 20, down 5.99% (-$0.0319), versus the S&P 500's 3.70% decline. Shares are 95.1% below their 52-week high of $10.28, set on Nov 25, 2025 and 0.8% above the 52-week low of $0.497, near the bottom of the past year's range. CVRX is down 92.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 94.9%.

CVRx has posted a net loss over the last twelve months (EPS of -$2.00), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CVRx

Company profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors.

Industry
Medical/Dental Instruments
CEO
Mr. Kevin Hykes
Headquarters
Minneapolis, MN
Employees
223
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, CVRx generated $56.7 million in revenue, up 10.4% from fiscal 2024, its 5th consecutive year of revenue growth. CVRx reported a net loss of $53.3 million, compared with a loss of $60.0 million a year earlier. Gross margin was 85.3% (up from 83.8%) and operating margin -90.5%.

CVRx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$56.65M$51.29M$39.30M$22.47M$13.04M
Growth+10.45%+30.53%+74.89%+72.36%+115.36%
Net income$-53.31M$-59.97M$-41.20M$-41.43M$-43.08M
EPS (diluted)$-2.04$-2.65$-1.99$-2.02$-4.16

Analyst forecast

Forecast

Consensus (7 analysts)

none

Avg. price target

$4.58+814.17%

  • Strong buy 0
  • Buy 3
  • Hold 3
  • Sell 0
  • Strong sell 1

Target range

Low $3.50High $6.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.49 vs $-0.49

CVRX news

All CVRX news

CVRx peers

Health Care sector
CVRX peer companies
CompanyPrice% ChgMarket capCompare
DRIODarioHealth Corp.1.32-8.33%$14.90Mvs CVRX
CTSOCytosorbents Corporation4.16-18.91%$13.12Mvs CVRX
SNWVSANUWAVE Health Inc.1.50-5.66%$12.90Mvs CVRX
MODDModular Medical Inc.1.68-11.81%$16.36Mvs CVRX
RVPRetractable Technologies Inc.0.558-6.84%$16.70Mvs CVRX
BEATHeartbeam Inc.0.2751-10.94%$17.42Mvs CVRX
GUTSFractyl Health Inc.0.82-14.16%$10.88Mvs CVRX
FEMYFemasys Inc.1.240.00%$10.73Mvs CVRX

Indexes, lists and sector

CVRx stock FAQ

What is CVRx's stock price today?

CVRX last traded at $0.501 as of Nov 20, 4:00 PM EST, down 5.99% on the day. Prices are delayed at least 15 minutes.

Who is CVRx's CEO?

Mr. Kevin Hykes is the chief executive officer of CVRx Inc., which has about 223 employees.

What is the CVRX 52-week high?

The 52-week high for CVRX is $10.28 and the 52-week low is $0.497. The stock is currently 95.1% below its high.

Compare CVRX